COMMUNIQUÉS West-GlobeNewswire

Nicox: Issuing and admission to trading on the Euronext regulated market in Paris of 597,897 new shares awarded to existing Aciex shareholders following the US FDA's approval of ZERVIATE
08/06/2017
Press Release Nicox announces the issuing and admission to trading on the Euronext regulated market in Paris of 597,897 new shares awarded to existing Aciex shareholders following the US FDA's approval of the new drug [...]
Solon Eiendom ASA - Primary insider notification
08/06/2017
SOLON EIENDOM ASA STOCK EXCHANGE ANNOUNCEMENT Solon Eiendom ASA - Primary insider notification (Oslo, Norway, 8 June 2017) Solon Eiendom ASA Chairman of the Board Simen Thorsen (through his wholly owned company Hortulan [...]
CROSSJECT : point d'activité
08/06/2017
Point d'activité Confirmation du calendrier des dépôts d'AMM Dijon, le 8 juin 2017 CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ), « specialty pharma » qui développe un portefeuille de médicaments combinés innovants [...]
CROSSJECT : Information relative au nombre total de droits de vote et d'actions composant le capital social
08/06/2017
Information relative au nombre total de droits de vote et d'actions composant le capital social 8 juin 2017 CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ), « specialty pharma » qui développe un portefeuille de [...]
Eckert & Ziegler BEBIG: Paola Eckert-Palvarini élue membre du Conseil d'administration.
08/06/2017
Communiqué de presse INFORMATIONS RÉGLEMENTÉES Seneffe, 8 juin 2017. Lors de l'Assemblée générale annuelle qui s'est tenue aujourd'hui à Seneffe (Belgique), les actionnaires de Eckert & Ziegler BEBIG SA ont nommé [...]
The IPO of Silmäasema Oyj has been oversubscribed and the final subscription price is EUR 6.90 per share
08/06/2017
Stock Exchange Release 8 June 2017, at 3 p.m. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, HONG KONG, SOUTH AFRICA, SINGAPORE OR JAPAN OR ANY [...]
HomeVi announces that PAI Partners has entered into exclusive negotiations with ICG and Yves Journel for the sale of a majority stake in the DomusVi group
08/06/2017
Suresnes, June 8th, 2017 - 9:30 am HomeVi S.A.S. ("HomeVi") today announced that its controlling shareholder, PAI Partners, has entered into exclusive negotiations with Intermediate Capital Group ("ICG") and Sagesse [...]
VALNEVA annonce la mise à disposition des documents préparatoires aux Assemblées d'actionnaires
08/06/2017
Valneva annonce la mise à disposition des documents préparatoires aux Assemblées d'actionnaires Lyon (France), 8 juin 2017 - Les actionnaires de la société Valneva SE (ci-après "Valneva" ou " le Groupe") sont invités à [...]
MDxHealth Launches CE-Marked SelectMDx IVD PCR Kit and UrNCollect Device
08/06/2017
NEWS RELEASE / REGULATED INFORMATION / INSIDE INFORMATION / FOR EX-US ONLY IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CEST, June 08, 2017 - MDxHealth SA (Euronext: MDXH.BR) today announced the launch in Europe and other [...]
MDxHealth lance le kit IVD PCR SelectMDx marqué CE et le dispositif UrNCollect
08/06/2017
COMMUNIQUE DE PRESSE / INFORMATION REGLEMENTAIRE / I NFORMATION PRIVILEGIEE / POUR EX-US SEULEMENT IRVINE, CA et HERSTAL, BELGIQUE - 07:00 CEST, le 08 juin 2017 - MDxHealth SA (Euronext: MDXH.BR) a annoncé aujourd'hui [...]
Actelion provides an update on the Phase III IMPACT program with cadazolid in CDAD
08/06/2017
ALLSCHWIL, SWITZERLAND - 08 June 2017 - Actelion Ltd (SIX: ATLN) today provided an update on the Phase III program IMPACT to investigate the efficacy and safety of Actelion's novel anti-infective cadazolid versus [...]
Bone Therapeutics SA : completes patient recruitment for pivotal interim analysis of Phase III Osteonecrosis trial with PREOB®
08/06/2017
Regulated information Bone Therapeutics completes patient recruitment for pivotal interim analysis of Phase III Osteonecrosis trial with PREOB ® Positive results could lead to further validation of Company's bone-cell [...]
Bone Therapeutics SA : finalise le recrutement des patients pour l'analyse intermédiaire de l'étude de Phase III avec PREOB® dans l'ostéonécrose
08/06/2017
Information réglementée Bone Therapeutics finalise le recrutement des patients pour l'analyse intermédiaire de l'étude de Phase III avec PREOB ® dans l'ostéonécrose Des résultats positifs permettraient de poursuivre la [...]
VALNEVA : Déclaration d'actions et de droits de vote - Mai 2017
07/06/2017
VALNEVA Déclaration d'actions et de droits de vote - MAI 2017 Dénomination sociale : VALNEVA Adresse du siège social : World Trade Center Lyon, Tour Oxygène, 10-12 Boulevard Marius Vivier Merle, 69003 Lyon Marché [...]
Novartis interim results from global, pivotal CTL019 trial show durable complete responses in adults with r/r DLBCL
07/06/2017
At interim analysis, three-month overall response rate (ORR) was 45%, with 37% complete response (CR); all patients in CR at three months remained in CR at data cutoff Best ORR was 59%, with 43% achieving CR; full [...]
Medtronic Initiates U.S. Launch of World's First Hybrid Closed Loop System for Type 1 Diabetes
07/06/2017
The MiniMed(TM) 670G System Features the Company's Most Advanced SmartGuard(TM)HCL Technology and New Guardian(TM) Sensor 3 DUBLIN - June 7, 2017 - Medtronic plc (NYSE:MDT), today announced the U.S. launch of the [...]
Oxford BioMedica plc: Oxford BioMedica notes FDA Advisory Committee to review CTL019
07/06/2017
Oxford BioMedica notes FDA Advisory Committee to review CTL019 London, UK - 7 June 2017: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE:OXB), a leading gene and cell therapy group, notes that the US Food [...]
Around the World in 365 Days - Taping the World for Health
07/06/2017
ALBUQUERQUE, N.M., June 07, 2017 (GLOBE NEWSWIRE) -- The Father of elastic, therapeutic taping and the genius of the Kinesio Taping® Method, Dr. Kenzo Kase looks to educate the world on the health benefits from Kinesio [...]
ObsEva SA Announces the Completion of a Phase 1 PK/PD Clinical Trial Evaluating Different Doses of OBE2109 and Add-Back Therapy
07/06/2017
- OBE2109 is a GnRH receptor antagonist currently in development as both a stand-alone treatment and with add-back therapy designed to address the needs of endometriosis and uterine fibroid patients - Geneva, [...]

Pages